| 摘要: | 神經退化性疾病在全世界是一個嚴重的問題，影響人腦中的神經元並引起神經細胞的退化或死亡，導致運動障礙或身心功能障礙。神經退化性疾病的一個例子是帕金森氏症(Parkinson’s disease; PD)，目前並沒有可治癒或阻止帕金森氏症惡化的治療方法。本研究通過腹腔注射(Intraperitoneal injection; Ip) 1-甲基-4-苯基-1,2,3,6-四氫?m啶(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP)誘發小鼠帕金森氏症，探討電針(Electroacupuncture; EA)在陽陵泉(GB34)和太衝穴(LR3)穴位、鼻腔給予間質幹細胞(Mesenchymal stem cell; MSCs)以及電針與間質幹細胞兩者併用的作用。在MPTP模式小鼠滾輪式跑步機平衡測驗(Rotarod test)，我們發現電針(EA)組及兩者併用組在滾輪式跑步機平衡測驗(Rotarod test)測試的時間較長，間質幹細胞組比起MPTP組無明顯增加；此外，在MPTP模式小鼠之黑質緻密部(Substantia nigra pars compacta, SNc)腦區中酪氨酸羥化?(tyrosine hydroxylase)的免疫組織化學分析顯示，電針(EA)組及兩者併用組可觀察到較多巴胺神經元，而單獨使用間質幹細胞組比起MPTP組無明顯差別。以流氏細胞儀測試所分離之間質幹細胞之CD90+ CD44+含量，結果顯示所分離出間質幹細胞中CD90+ CD44+約為8.92-14.10 %。由以上結果顯示，電針穴位治療可能是帕金森氏症患者的有效策略，本研究中所使用的間質幹細胞濃度偏低可能是間質幹細胞沒有療效的原因。
Neurodegenerative diseases are a serious problem worldwide, affecting neurons in the human brain and causing the deterioration or death of nerve cells, leading to movement disorders or physical and mental dysfunction. An example of a neurodegenerative disease is Parkinson's disease (PD), which currently has no treatment to cure or prevent the progression of Parkinson's disease. In this study, we used intraperitoneal injection (i.p.) of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP) to induce mouse Parkinson's disease and explored the beneficial effects of electroacupuncture (EA) at Yanglingquan (GB34) and Taichong (LR3) acupoints, nasal administration of mesenchymal stem cells (MSCs) and their combination. In MPTP-treated mice of the Rotarod test, the latency of the EA group and the combination of the EA plus nasal administration of (MSCs) were significantly longer than that of MPTP only group. The latency of MSC group was no significant increased compared with the MPTP only group. The immunohistochemical analysis of tyrosine hydroxylase in the substantia nigra pars compacta (SNc) brain region of MPTP-treated mice showed that more TH-positive cells were observed in the (EA) group and the combination group compared with MPTP only group. There was no significant difference between the MSC group alone and the MPTP only group. The CD90+ CD44+ content of the isolated mesenchymal stem cells was tested by flow cytometry. The results showed that the CD90+ CD44+ in the isolated mesenchymal stem cells was about 8.92-14.10%. The above results show that EA treatment may be an effective strategy for patients with Parkinson's disease. The low concentration of mesenchymal stem cells used in this study may be the reason why mesenchymal stem cells treatment has no curative effect. |
